Genetic Mutation As Biomarker for Advanced Cancer Patients Receiving Apatinib: an Analysis Based on Whole Exome Sequencing.

Yong Fang,Yulong Zheng,Jun Chen,Jieer Ying,Haizhou Lou,Enguo Chen,Da Li,Chuangzhou Rao,Fangmin Du,Jiawei Shou,Hongming Pan

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e24219

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e24219 Background: Apatinib, a VEGFR-2 inhibitor, has shown significant anti-tumor effects in the treatment of advanced solid tumors. However no biomarkers identified to predict the benefits treated with apatinib. In this retrospective analysis, using whole exome sequencing (WES) analysis based on the next-generation sequencing (NGS) detection, the gene mutation was assessed to identify the possible biomarkers associated with survival benefit. Methods: 39 pts with advanced solid cancer resistant to routine chemotherapy or radiotherapy were enrolled. All the pts were divided into 2 groups, 26 pts with PFS≥90days and 13 pts with PFS < 90 days. WES was performed to depict the comprehensive genomic features. The captured sequencing data was further processed to identify somatic mutations. The FISHER Exact statistical test was used to find significant differentially genes between 2 groups. Results: Based on the WES detection, ERICH3, CNTNAP3 and MUC6 p.G1946D mutation only detected in pts with PFS≥90 days, while no mutation of these 3 genes in pts with PFS < 90 days. Pathway analysis showed that ERICH3 and CNTNAP3 mutation could induce the change of drug target or affect the intake of drug through the cell membrane, the MUC6 mutation could change the cell adhesion signal pathway. The differences were also observed in the following gene mutation between 2 groups. 1. COL6A3, MYLK, and BMPR1B, could activate bypass vascular signaling pathway; 2. SLC2A3 and YME1L1, could influence the concentration of reactive oxygen species in tumor tissues; 3. ICAM5, could affect tumor invasion signal pathway. All the above 3 signal pathways with gene mutation were related to drug-resistance. Conclusions: The ERICH3, CNTNAP3 and MUC6 gene mutation might be associated with longer PFS. The mutation in drug-resistant related pathway might affect the survival benefit. Further prospective study is needed to discover the possible biomarker of Apatinib. Table 1 Mutant status of ERICH3, CNTNAP3 and MUC6 p.G1946D. N PFS≥90 n (%) PFS < 90, n (%) P ERICH3 wild type 32 0 (0) 32(100) < 0.0001 mutation 7 7 (100) 0 (0) CNTNAP3 wild type 32 0 (0) 32(100) < 0.0001 mutation 7 7 (100) 0 (0) MUC6 p.G1946D wild type 32 0 (0) 32(100) < 0.0001 mutation 7 7 (100) 0 (0)